Kidney Fibrosis Treatment Market

Kidney Fibrosis Treatment Market - Global Industry Analysis, Size, Share, Trends, Growth, and Forecasts, 2021-2031

Kidney Fibrosis Treatment Market – Overview

The global kidney fibrosis treatment market is expected to expand at a healthy rate from 2021 to 2031 (forecast period). Kidney fibrosis is induced by an abnormal accumulation of extracellular matrix and represents a failure of the kidney's wound healing process. Moreover, kidney fibrosis is a method that leads to end-stage renal disease. In the past few years, the need for kidney fibrosis treatment has increased due to a spike in the number of cases of chronic kidney illnesses and kidney fibrosis and an increase in the patient population base. Furthermore, renal fibrosis causes specific kidney damage or dysfunction. A few of the causes of kidney fibrosis include diabetes, cardiac difficulties, and a family background of chronic kidney disease.

Kidney Fibrosis Treatment Market – Competitive Landscape

Some of the prominent players active in the global kidney fibrosis treatment market are Pfizer Inc., Merck & Co., F. Hoffman-La Roche Ltd., La Jolla Pharmaceutical Company, Galectin Therapeutics, InterMune Inc., Genzyme Corporation, ProMetic Life-Sciences Inc., BioLine Rx Ltd, among others.

To expand and strengthen their market presence, key market players are actively pursuing inorganic marketing tactics such as collaborations, investments, technological innovations, acquisitions, and R&D activities.

Kidney Fibrosis Treatment Market – Trends and Opportunities

The increased prevalence of chronic illnesses as a result of improper eating habits has led to kidney fibrosis cases, which is expected to boost the global kidney fibrosis treatment market in the upcoming years. Moreover, the aging population and widespread awareness of kidney fibrosis therapy are projected to drive the global kidney fibrosis treatment market. Furthermore, the rising prevalence of obesity as a consequence of changing food habits has led to an increase in kidney issues, which is anticipated to push the global kidney fibrosis treatment market growth.

Constant technological innovation has resulted in the emergence of safe and effective medicines for the treatment of chronic kidney illnesses, which is expected to aid the growth of the global kidney fibrosis treatment market. Moreover, due to the growing survival rate and efficiency of these treatments in renal patients, the advent of new drugs into the market, combined with favorable government initiatives, is projected to fuel the expansion of the global kidney fibrosis treatment market. Furthermore, emerging countries such as China and India have considerable potential opportunities in the global kidney fibrosis treatment market due to increased medical tourism rates.

Kidney Fibrosis Treatment Market – Regional Landscape

The kidney fibrosis treatment market in North America is anticipated to witness considerable growth due to an increase in the population base suffering from kidney illnesses. Moreover, the growing introduction of end-stage kidney disorder treatments in countries such as the United States is expected to create profitable growth avenues for the kidney fibrosis treatment market in North America over the assessment period.

The increase in CRO (Contract Research Organization) operations and the spike in healthcare spending in the United States and Canada are projected to contribute to the regional market expansion. According to the CDC (Centers for Disease Control and Prevention), about 37 million adult individuals were expected to be impacted by chronic kidney disease in 2019. This represented 15% of the overall adult population in the United States. Aside from that, the CDC reports that glomerulonephritis and polycystic kidney disease affect children over the age of 18 in the United States. The aforementioned aspects are projected to boost the demand for kidney fibrosis therapy in the United States, consequently influencing regional market dynamics.

The Asia Pacific kidney fibrosis treatment market is expected to expand due to growing medical expenditure, increasing disposable income, expanding CRO operations, and growing medical treatment.


Copyright © Transparency Market Research, Inc. All Rights reserved